| Title |
Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis
|
|---|---|
| Published in |
Drugs, September 2018
|
| DOI | 10.1007/s40265-018-0984-5 |
| Pubmed ID | |
| Authors |
Laura E. Baldassari, Robert J. Fox |
| Abstract |
Despite the fact that majority of patients with multiple sclerosis (MS) have relapsing-remitting disease, many transition to secondary progressive disease (SPMS) over time. This transition is thought to be related to neurodegenerative processes increasingly predominating over inflammatory processes as the driving forces of disability. However, some patients initially present with primary progressive disease (PPMS) that is characterized by a gradual accumulation of neurological symptoms and subsequent disability accumulation. The treatment of both PPMS and SPMS, collectively referred to as progressive MS, has proven quite challenging due to the multifactorial and poorly understood pathophysiology of multiple sclerosis in general, specifically that of progressive disease. The purpose of this article is to discuss important clinical and pathophysiologic differences between relapsing and progressive forms of MS, review previous notable trials of drugs in progressive MS, examine current literature regarding recent and promising progressive MS treatments, and discuss future considerations for progressive MS therapeutics and management. Specifically, the current evidence regarding treatment of progressive MS with ocrelizumab, simvastatin, ibudilast, alpha-lipoic acid, high-dose biotin, siponimod, and cell-based therapies are discussed. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 43% |
| United States | 2 | 29% |
| Portugal | 1 | 14% |
| United Kingdom | 1 | 14% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 4 | 57% |
| Members of the public | 3 | 43% |
Mendeley readers
The data shown below were compiled from readership statistics for 175 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 175 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 31 | 18% |
| Student > Master | 19 | 11% |
| Unspecified | 16 | 9% |
| Researcher | 14 | 8% |
| Student > Ph. D. Student | 13 | 7% |
| Other | 30 | 17% |
| Unknown | 52 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 21% |
| Neuroscience | 22 | 13% |
| Unspecified | 16 | 9% |
| Biochemistry, Genetics and Molecular Biology | 13 | 7% |
| Nursing and Health Professions | 6 | 3% |
| Other | 20 | 11% |
| Unknown | 62 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 October 2018.
All research outputs
#6,518,909
of 23,105,443 outputs
Outputs from Drugs
#1,121
of 3,289 outputs
Outputs of similar age
#117,285
of 341,066 outputs
Outputs of similar age from Drugs
#19
of 33 outputs
Altmetric has tracked 23,105,443 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 3,289 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,066 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.